Chopera, Denis Rutendo.Mann, Jaclyn Kelly.Mwimanzi, Philip.Omarjee, Saleha.Kuang, Xiaomei T.Ndabambi, Nonkululeko.Goodier, Sarah A.Martin, Eric.Naranbhai, Vivek.Abdool Karim, Salim Safurdeen.Abdool Karim, Quarraisha.Brumme, Zabrina L.Ndung'u, Peter Thumbi.Williamson, Carolyn.Brockman, Mark A.2016-10-242016-10-2420132013Chopera, D.R., Mann, J.K., Mwimanzi, P., Omarjee, S., Kuang, X.T., Ndabambi, N., Goodier, S., Martin, E., Naranbhai, V., Karim, S.A. and Karim, Q.A. 2013. No evidence for selection of HIV-1 with enhanced Gag-Protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PloS one 8(8), e71758.http://dx.doi.org/10.1371/journal.pone.0071758.http://hdl.handle.net/10413/13535CAPRISA, 2013.Background: Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections. To investigate this, we assessed the in vitro function of gag-protease and nef sequences from participants who acquired HIV-1 during the CAPRISA 004 1% tenofovir microbicide gel trial. Methods and Results: We isolated the earliest available gag-protease and nef gene sequences from 83 individuals and examined their in vitro function using recombinant viral replication capacity assays and surface protein down regulation assays, respectively. No major phylogenetic clustering and no significant differences in gag-protease or nef function were observed in participants who received tenofovir gel versus placebo gel prophylaxis. Conclusion: Results indicate that the partial protective effects of 1% tenofovir gel use in the CAPRISA 004 trial were not offset by selection of transmitted/early HIV-1 variants with enhanced Gag-Protease or Nef fitness.enPeer reviewed journal article